CompletedNot Applicable

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Iraq763 participantsStarted 2020-09-01

Plain-language summary

This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed SpA patients * 18 years of age and older. * Did not receive previous other biological treatments. * Patients have at least 1 year on Enbrel. Exclusion Criteria: * Had previously used another biological treatments. * Use of etanercept for less than 1 year duration.

What they're measuring

Percentage of Participants With 7 Years Adherence to Etanercept

Timeframe: 7 years [from the data retrieved and observed in 1 month of this study]

Trial details

NCT IDNCT04507776

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-10-01

Results submitted2021-09-03

View on ClinicalTrials.gov More Spondyloarthrosis trials